Skip to main content
Log in

Selectivity Improvement for Spectrofluorimetric Determination of Oseltamivir Phosphate in Human Plasma and in the Presence of Its Degradation Product

  • ORIGINAL ARTICLE
  • Published:
Journal of Fluorescence Aims and scope Submit manuscript

Abstract

A simple and sensitive spectrofluorimetric method has been developed and validated for determination of oseltamivir phosphate (OSP). The proposed method is based on condensation reaction of the primary amino group of OSP with ninhydrin and phenylacetaldehyde in buffered medium (pH 6.5). The formed yellow fluorescent product exhibits excitation and emission maxima at 390 and 460 nm, respectively. The selectivity improvement of our proposed method is based on the water insolubility of the oseltamivir carboxylic acid (OSC) the active metabolite of OSP, which contains the same primary amino group as OSP but cannot, condensed with ninhydrin and phenylacetaldehyde reagents. The different experimental parameters affecting the formation and stability of the reaction product were carefully studied and optimized. The fluorescence intensity concentration plot is rectilinear in the range of 2–15 μg ml−1 with detection and quantitation limits of 0.32 and 0.98 μg ml−1, respectively. The proposed method was successfully applied for determination of OSP in commercial capsules, suspension and spiked human plasma with good percentage recovery. In addition, the developed procedure was extended to study the stability of OSP under different stress conditions; including acid and alkali hydrolysis, oxidation, photolysis, and thermal degradation. Furthermore, the kinetic of alkaline and acidic degradation of the cited drug were investigated. The apparent first order degradation rate constants were 0.258 and 0.318 K h−1 with half times of 2.68 and 2.17 h, for acidic and alkaline degradation, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Nicholson K, Aoki F, Osterhaus A, Trottier S, Carewicz O, Mercier C, Rode AN, Kinnersley P (2000) Ward, efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845–1850

    Article  CAS  PubMed  Google Scholar 

  2. Wiltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D, Herron W (2000) Development of a high-performance liquid chromatographic–mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 745:373–388

    Article  CAS  PubMed  Google Scholar 

  3. Dreitlein WB, Maratos J, Brocavich J (2001) Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clin Ther 23:327–355

    Article  CAS  PubMed  Google Scholar 

  4. McClellan K, Perry CM (2001) Oseltamivir: a review of its use in influenza. Drugs 61:263–283

    Article  CAS  PubMed  Google Scholar 

  5. Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55:i5–i21

    Article  CAS  PubMed  Google Scholar 

  6. Green MD, Nettey H, Wirtz RA (2008) Determination of oseltamivir quality by colorimetric and liquid chromatographic methods, emerging infect. Dis 14:552–556

    CAS  Google Scholar 

  7. Raut CS, Gharge DS, Dhabale PN, Gonjari ID, Hosmani AH, Hosmani AH (2010) Development and validation of oseltamivir phosphate in Fluvir® by UV spectrophotometer. Int J PharmTech Res 2:363–366

    CAS  Google Scholar 

  8. Ashish AT, Rahul JK, Pramila T, Udaykumar AB, Kiran BD (2011) Development, validation and application of UV-spectrophotometric method for the determination of oseltamivir phosphate in bulk and pharmaceutical dosage form. Int J ChemTech Res 3:569–573

    Google Scholar 

  9. Bano T, Yadav G, Dudhe R (2013) Development and validation of oseltamivir phosphate API by UV-spectrophotometer, global J. Pharmacol 7:294–297

    CAS  Google Scholar 

  10. Kumar JVS, Prasanthi S, Guravaiah M, Sekaran CB (2012) Application of potassium permanganate to the spectrophotometric determination of oseltamivir phosphate in bulk and capsules. Asian J Pharm Clin Res 5:18–22

    Google Scholar 

  11. Sahu S, Acharya S, Chourasia A, Asati A (2012) Method development and validation of oseltamivir phosphate in bulk drug by UV spectroscopy. Int J Pharm Pharm Sci 4:194–196

    CAS  Google Scholar 

  12. Ashish AT, Pramila T (2011) Simple extractive colorimetric determination of oseltamivir phosphate by ion-pair complexation method in bulk and capsule dosage form. Int J Res Pharm Biomed Sci 2:543–547

    Google Scholar 

  13. Narasimhan B, Abida K, Srinivas K (2008) Stability indicating RP-HPLC method development and validation for oseltamivir API. Chem Pharm Bull 56:413–417

    Article  CAS  PubMed  Google Scholar 

  14. Joseph CJ, Geneste C, Laborde-Kummer E, Gheyouche R, Boudis H, Dubost JP (2007) Development and validation of a rapid HPLC method for the determination of oseltamivir phosphate in Tamiflu® and generic versions. J Pharm Biomed Anal 44:1008–1013

    Article  Google Scholar 

  15. Lindegårdh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon P, White NJ, Day NPJ (2007) Development and validation of a liquid chromatographic–tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J Chromatogr B 859:74–83

    Article  Google Scholar 

  16. Heinig K, Bucheli F (2008) Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography–tandem mass spectrometry. J Chromatogr B 876:129–136

    Article  CAS  Google Scholar 

  17. Kanneti R, Bhavesh D, Paramar D, Bhatt PA (2011) Development and validation of a high-throughput and robust LC–MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies. Biomed Chromatogr 25:727–733

    Article  CAS  PubMed  Google Scholar 

  18. Chan D, Tarbin J, Sharman M, Carson M, Smith M, Smith S (2011) Screening method for the analysis of antiviral drugs in poultry tissues using zwitterionic hydrophilic interaction liquid chromatography/tandem mass spectrometry. Anal Chim Acta 700:194–200

    Article  CAS  PubMed  Google Scholar 

  19. Chabai H, Ouarezki R, Guermouche S, Guermouche MH (2011) Rapid determination of oseltamivir phosphate in pharmaceutical preparation using monolithic silica HPLC column. J Liq Chromatogr Relat Technol 34:1913–1924

    Article  CAS  Google Scholar 

  20. Kromdijk W, Rosing H, Van den Broek MPH, Beijnen JH, Huitema ADR (2012) Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B 891:57–63

    Article  Google Scholar 

  21. Laborde KE, Gaudin K, Joseph CJ, Gheyouche R, Boudis H, Dubost JP (2009) Development and validation of a rapid capillary electrophoresis method for the determination of oseltamivir phosphate in Tamiflu® and generic versions. J Pharm Biomed Anal 50:544–546

    Article  Google Scholar 

  22. Avramov-Ivić ML, Petrović SD, Mijin DŽ, Drljević-Đurić KM (2011) The qualitative determination of oseltamivir phosphate in tamiflu® capsule by cyclic voltammetry. Hem Ind 65:87–91

    Article  Google Scholar 

  23. Omar M, Mostafa I, Derayea S (2015) Development and validation of stability-indicating spectrofluorometric method for determination of H1N1 antiviral drug (oseltamivir phosphate) in human plasma through Hantzsch reaction. RSC Adv 5:27735–27742

    Article  CAS  Google Scholar 

  24. Walash M, Belal F, El-Enany N, El-Maghrabey M (2012) Spectrofluorimetric determination of oseltamivir phosphate through derivatization with o-phthalaldehyde. Application to pharmaceutical preparations with a preliminary study on spiked plasma samples, Luminescence 27:511–518

    CAS  PubMed  Google Scholar 

  25. Aydoğmuş Z (2009) Simple and sensitive spectrofluorimetric method for the determination of oseltamivir phosphate in capsules through derivatization with fluorescamine. J Fluoresc 19:673–679

    Article  PubMed  Google Scholar 

  26. ICH Harmonized Tripartite Guideline Validation of analytical procedures: text and methodology, Q2(R1) 2005.Current step 4 version, parent guidelines on methodology dated November 6, 1996, incorporated in November 2005

  27. Pesez M, Bartos J (1974) Colorimetric and Fluorimetric analysis of organic compounds and drugs. Marcel Dekker, Inc., New York

    Google Scholar 

  28. Abdellatef HE, Khalil HM (2003) Colorimetric determination of gabapentin in pharmaceutical formulation. J Pharm Biomed Anal 31:209–214

    Article  CAS  PubMed  Google Scholar 

  29. Rahman N, Kashif M (2003) Application of ninhydrin to spectrophotometric determination of famotidine in drug formulations. Farmaco 58:1045–1050

    Article  CAS  PubMed  Google Scholar 

  30. Omar MA, Hammad MA, Nagy DM, Aly AA (2015) Development of spectrofluorimetric method for determination of certain aminoglycoside drugs in dosage forms and human plasma through condensation with ninhydrin and phenyl acetaldehyde. Spectrochim Acta A Mol Biomol Spectrosc 136:1760–1766

    Article  CAS  PubMed  Google Scholar 

  31. Yoe JH, Jones AL (1944) Ind. Eng. Chem Anal 16:111

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mahmoud A. Omar.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Omar, M.A., Derayea, S.M. & Mostafa, I.M. Selectivity Improvement for Spectrofluorimetric Determination of Oseltamivir Phosphate in Human Plasma and in the Presence of Its Degradation Product. J Fluoresc 27, 1323–1330 (2017). https://doi.org/10.1007/s10895-017-2066-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10895-017-2066-6

Keywords

Navigation